计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| L125518-5mg |
5mg |
现货 ![]() |
| |
| L125518-10mg |
10mg |
现货 ![]() |
| |
| L125518-50mg |
50mg |
现货 ![]() |
| |
| L125518-250mg |
250mg |
现货 ![]() |
| |
| L125518-1g |
1g |
现货 ![]() |
| |
| L125518-5g |
5g |
现货 ![]() |
|
| 别名 | 乐伐替尼 | 仑伐替尼 | 乐法替尼 |
|---|---|
| 英文别名 | LENVATINIB [MI] | UNII-EE083865G2 | AS-16203 | LEV | NSC800781 | NSC-800781 | DB09078 | AKOS021983298 | LENVATINIB [INN] | AKOS015838040 | BCP9000633 | DTXSID30182868 | 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | Lenvatinib (E7080) |
| 储存温度 | -20°C储存,充氩 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | FMS 相关受体酪氨酸激酶 4 抑制剂;激酶插入域受体抑制剂 |
| 产品介绍 |
Lenvatinib (E7080)是一种多靶点抑制剂,作用于VEGFR2(KDR)/VEGFR3(Flt-4)最有效,IC50为4 nM/5.2,对VEGFR1/Flt-1作用效果稍弱,作用于VEGFR2/3比作用于FGFR1, PDGFRα/β选择性高10倍左右。Phase 3。 Lenvatinib is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors. Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β. Phase 3. Lenvatinib is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors. |
| 纯度 | ≥99% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 488196334 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide |
| INCHI | 1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28) |
| InChi Key | WOSKHXYHFSIKNG-UHFFFAOYSA-N |
| Smiles | COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl |
| Isomeric SMILES | COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl |
| 关联CAS | 417716-92-8 |
| MeSH Entry Terms | 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide;4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide;4-(3-chloro-4-(N'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxami |
| 分子量 | 426.85 |
| Reaxy-Rn | 12096874 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=12096874&ln= |
| 溶解性 | DMSO 40 mg/mL (93.7 mM); Water <1 mg/mL (<1 mM); Ethanol <1 mg/mL (<1 mM) |
|---|---|
| 敏感性 | 对空气敏感;对热敏感 |
| 分子量 | 426.900 g/mol |
| XLogP3 | 2.800 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 5 |
| 可旋转键计数Rotatable Bond Count | 6 |
| 精确质量Exact Mass | 426.109 Da |
| 单同位素质量Monoisotopic Mass | 426.109 Da |
| 拓扑极表面积Topological Polar Surface Area | 116.000 Ų |
| 重原子数Heavy Atom Count | 30 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 634.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 | |
| 分析证书 | L125518 |
¥99.90
| 1. Musumeci F, Radi M, Brullo C, Schenone S. (2012) Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.. J Med Chem, 55 (24): (10797-822). [PMID:23098265] |
| 2. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J et al.. (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.. Lancet, 391 (10126): (1163-1173). [PMID:29433850] |
| 3. Mengming Xia, Xueyi Song, Zebei Lu, Yu Wang, Quan Zhou, Peiwu Geng, Shuanghu Wang, Yunfang Zhou, Qingjun Wu, Aixia Han. (2023) Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC-MS/MS. Thoracic Cancer, 14 (33): (3331-3341). [PMID:37771131] [10.1111/1759-7714.15125] |
| 4. Jie Yao, Shuming Tang, Chenyan Shi, Yunzhi Lin, Lanlan Ge, Qinghua Chen, Baoru Ou, Dongyu Liu, Yuyang Miao, Qiujie Xie, Xudong Tang, Jia Fei, Guangyi Yang, Jun Tian, Xiaobin Zeng. (2023) Isoginkgetin, a potential CDK6 inhibitor, suppresses SLC2A1/GLUT1 enhancer activity to induce AMPK-ULK1-mediated cytotoxic autophagy in hepatocellular carcinoma. Autophagy, 19 (4): (1221-1238). [PMID:36048765] [10.1080/15548627.2022.2119353] |
| 5. Peisen Zheng, Yiqun Xia, Xin Shen, Hui Lu, Yinghua Chen, Chenxin Xu, Chenyu Qiu, Yafei Zhang, Peng Zou, Ri Cui, Xiaoying Huang. (2024) Combination of TrxR1 inhibitor and lenvatinib triggers ROS-dependent cell death in human lung cancer cells. International Journal of Biological Sciences, 20 (1): (249-264). [PMID:38164168] [10.7150/ijbs.86160] |
| 6. Yilan Huang, Siwei Wang, Xiaojun Zhang, Chen Yang, Sikai Wang, Hongxia Cheng, Aiwu Ke, Chao Gao, Kun Guo. (2024) Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway. PHARMACOLOGICAL RESEARCH, 200 (107082). [PMID:38280440] [10.1016/j.phrs.2024.107082] |
| 7. Jie Yao, Haoqiang Wan, Jingmei Zhang, Wanying Shen, Xiaofang Wei, Chenyan Shi, Baoru Ou, Dongyu Liu, Lanlan Ge, Jia Fei, Xiaobin Zeng. (2024) Tubuloside B, a major constituent of Cistanche deserticola, inhibits migration of hepatocellular carcinoma by inhibiting Hippo-YAP pathway. PHYTOMEDICINE, 129 (155552). [PMID:38552378] [10.1016/j.phymed.2024.155552] |